Latent class analysis identifies functional decline with Amsterdam IADL in preclinical Alzheimer's disease

INTRODUCTION: Trials in Alzheimer's disease (AD) now include participants at the earliest stages to prevent further decline. However, the lack of tools sensitive to subtle functional changes in early-stage AD hinders the development of new therapies as it is difficult to prove their clinical re...

Descripción completa

Detalles Bibliográficos
Autores principales: Villeneuve, Sarah-Christine, Houot, Marion, Cacciamani, Federica, Verrijp, Merike, Dubois, Bruno, Sikkes, Sietske, Epelbaum, Stéphane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804616/
https://www.ncbi.nlm.nih.gov/pubmed/31650012
http://dx.doi.org/10.1016/j.trci.2019.08.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804616/
https://www.ncbi.nlm.nih.gov/pubmed/31650012
http://dx.doi.org/10.1016/j.trci.2019.08.009

Ejemplares similares